Knut Tore Lappegård (born 1961) Specialist in internal medicine, senior consultant and adjunct professor. He has contributed the concept, manuscript design and literature search.
The author has completed the ICMJE form and reports no conflicts of interest.
Anna Bjerre (born 1957) MD PhD, specialist in paediatrics and head of the Section for Paediatric Nephrology. She has contributed literature search and manuscript revision.
The author has completed the ICMJE form and reports no conflicts of interest.
Geir E. Tjønnfjord (born 1953) Specialist in internal medicine and blood diseases, head of department and professor of haematology. He has contributed literature search and manuscript revision.
The author has completed the ICMJE form and reports the following conflicts of interest: he has received remuneration from Alexion Pharma Nordics.
Tom Eirik Mollnes (born 1956) Researcher and adjunct professor at the University of Tromsø and the University of Oslo. He has contributed literature search, manuscript revision and figure design.
The author has completed the ICMJE form and reports no conflicts of interest.
Research Laboratory
Nordland Hospital Bodø
and
Centre of Molecular Inflammation Research (SFF-CEMIR)
Norwegian University of Science and Technology
()
MAIN POINTS
The complement system is involved in a number of disease processes.
Inhibition of the complement system is central to the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
Complement inhibition may also be applicable to the treatment of other conditions.
Risitano AM, Ricklin D, Huang Y et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014; 123: 2094 – 101. [PubMed] [CrossRef]
7.
Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233 – 43. [PubMed] [CrossRef]
8.
Melis JP, Strumane K, Ruuls SR et al. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol 2015; 67: 117 – 30. [PubMed] [CrossRef]
9.
Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol 2012; 40: 18 – 26. [PubMed] [CrossRef]
10.
Nissen-Meyer LS, Tjønnfjord GE, Golebiowska E et al. Paroksysmal nattlig hemoglobinuri ved Oslo universitetssykehus 2000 – 10. Tidsskr Nor Legeforen 2015; 135: 1039-43. [PubMed] [CrossRef]
Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2015. E-publisert 11.4.
13.
Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643 – 57. [PubMed] [CrossRef]
14.
Diamante Chiodini B, Davin JC, Corazza F et al. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 2014; 133: e1764 – 8.
15.
Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 1840 – 7. [PubMed] [CrossRef]
16.
Kanakura Y, Ohyashiki K, Shichishima T et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol 2013; 98: 406 – 16. [PubMed] [CrossRef]
17.
Hillmen P, Muus P, Röth A et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162: 62 – 73. [PubMed] [CrossRef]
18.
Vilalta R, Lara E, Madrid A et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 2012; 27: 2323 – 6. [PubMed] [CrossRef]
19.
Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med 2013; 24: 492 – 5. [PubMed] [CrossRef]
20.
Martel C, Granger CB, Ghitescu M et al. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J 2012; 164: 43 – 51. [PubMed] [CrossRef]
21.
Ghirardo G, Benetti E, Poli F et al. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014; 18: E1 – 5. [PubMed] [CrossRef]
22.
Lonze BE, Zachary AA, Magro CM et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14: 459 – 65. [PubMed] [CrossRef]
23.
Charles Jennette J, Xiao H, Hu P. Complement in ANCA-associated vasculitis. Semin Nephrol 2013; 33: 557 – 64. [PubMed] [CrossRef]
24.
Kusner LL, Satija N, Cheng G et al. Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve 2014; 49: 749 – 56. [PubMed] [CrossRef]
25.
Pittock SJ, Lennon VA, McKeon A et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12: 554 – 62. [PubMed] [CrossRef]
26.
Sharp JA, Whitley PH, Cunnion KM et al. Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol 2014; 5: 406. [PubMed] [CrossRef]
27.
Shi J, Rose EL, Singh A et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123: 4015 – 22. [PubMed] [CrossRef]
28.
Macor P, Durigutto P, De Maso L et al. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum 2012; 64: 2559 – 67. [PubMed] [CrossRef]
29.
Dmytrijuk A, Robie-Suh K, Cohen MH et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008; 13: 993 – 1000. [PubMed] [CrossRef]
30.
Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006; 43: 107 – 21. [PubMed] [CrossRef]
31.
Falcão DA, Reis ES, Paixão-Cavalcante D et al. Deficiency of the human complement regulatory protein factor H associated with low levels of component C9. Scand J Immunol 2008; 68: 445 – 55. [PubMed] [CrossRef]
32.
Sprong T, Brandtzaeg P, Fung M et al. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 2003; 102: 3702 – 10. [PubMed] [CrossRef]
This article was published more than 12 months ago and we have therefore closed it for new comments.
Published: 20 October 2015
Tidsskr Nor Legeforen 20 October 2015
doi:
10.4045/tidsskr.15.0049
Received 13 January 2015, first revision submitted 21 June 2016, accepted 21 August 2015. Editor: Lise Mørkved Helsingen.
If you do not see the PDF file or want to save the file, you can right-click on the PDF icon. Select «Save target / file as ...» and then retrieve the PDF file in, for example, Acrobat Reader.